Comgest Global Investors S.A.S. raised its stake in Icon Plc (NASDAQ:ICLR) by 40.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 137,633 shares of the medical research company’s stock after acquiring an additional 39,500 shares during the period. Icon Plc accounts for approximately 0.4% of Comgest Global Investors S.A.S.’s portfolio, making the stock its 23rd largest position. Comgest Global Investors S.A.S. owned approximately 0.25% of Icon Plc worth $15,674,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ICLR. Shine Investment Advisory Services Inc. acquired a new position in Icon Plc in the second quarter valued at $103,000. Acrospire Investment Management LLC boosted its stake in Icon Plc by 20.1% in the second quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock valued at $117,000 after acquiring an additional 200 shares in the last quarter. Parallel Advisors LLC boosted its stake in Icon Plc by 20.7% in the second quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock valued at $133,000 after acquiring an additional 217 shares in the last quarter. Huntington National Bank boosted its stake in Icon Plc by 5.0% in the second quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock valued at $159,000 after acquiring an additional 77 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC acquired a new position in Icon Plc in the second quarter valued at $208,000. Institutional investors own 91.59% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Icon Plc (ICLR) Shares Bought by Comgest Global Investors S.A.S.” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.watchlistnews.com/icon-plc-iclr-shares-bought-by-comgest-global-investors-s-a-s/1705181.html.

Several equities analysts have issued reports on ICLR shares. Zacks Investment Research downgraded shares of Icon Plc from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. ValuEngine upgraded shares of Icon Plc from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. SunTrust Banks, Inc. restated a “buy” rating and issued a $138.00 price objective on shares of Icon Plc in a research note on Sunday, October 29th. Credit Suisse Group restated an “outperform” rating and issued a $120.00 price objective (up previously from $105.00) on shares of Icon Plc in a research note on Monday, October 16th. Finally, Robert W. Baird restated a “buy” rating and issued a $123.00 price objective on shares of Icon Plc in a research note on Thursday, October 12th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $121.00.

Shares of Icon Plc (NASDAQ ICLR) traded down $0.89 during trading hours on Wednesday, hitting $112.35. 241,200 shares of the stock were exchanged, compared to its average volume of 368,192. Icon Plc has a 1-year low of $73.76 and a 1-year high of $124.48. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $6,132.17, a PE ratio of 21.74, a price-to-earnings-growth ratio of 1.75 and a beta of 0.56.

Icon Plc (NASDAQ:ICLR) last announced its earnings results on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. The business had revenue of $440.30 million during the quarter, compared to analysts’ expectations of $438.09 million. Icon Plc had a net margin of 16.37% and a return on equity of 28.42%. The business’s revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.19 earnings per share. equities research analysts forecast that Icon Plc will post 5.36 earnings per share for the current fiscal year.

Icon Plc Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.